$MNOV News

MediciNova Provides Update On Recent Topline Results Of Its Phase 2 Clinical Trial Evaluating MN-001 For Treatment Of Nonalcoholic Fatty Liver Disease And Hypertriglyceridemia Associated With Type 2 Diabetes Mellitus; At End Of The 24-Week Period, Serum Triglycerides, Liver Fat, And Body Weight Were Also Reduced In The MN-001 Group Compared With Placebo, Although These Differences Did Not Reach Statistical Significance

MediciNova to Participate in the Maxim Growth Summit

MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles

MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints

MediciNova stock tumbles on mixed Phase 2 NAFLD trial data

MediciNova Announces Topline Results From MN-001-NATG-202, Its Phase 2 Clinical Trial Evaluating MN-001 (Tipelukast) For Treatment Of Hypertriglyceridemia And Nonalcoholic Fatty Liver Disease Associated With Type 2 Diabetes Mellitus; At Week 24, The MN-001 Group Continued To Show A Numerical Reduction From Baseline Value, Although The Difference Between The MN-001 And Placebo Groups Were Not Statistically Significant

MediciNova Completes Last Patient, Last Visit In The Double-Blind Portion Of COMBAT-ALS Phase 2B/3 Clinical Trial Evaluating MN-166 For The Treatment Of Amyotrophic Lateral Sclerosis

Roth Capital Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $6

MediciNova to Participate in Two Investor Conferences in September

MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MediciNova CEO Provides Shareholder Update

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

MediciNova Receives U.S. Patent Office Notice Of Allowance Covering The Use Of Ibudilast In The Treatment Of Glioblastoma

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

MediciNova to Participate at the 38th Annual ROTH Conference

HC Wainwright & Co. Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $10

MediciNova: Q4 Earnings Snapshot